Health Economics›Ovarian cancer›Maintenance after first-line therapy

Maintenance after first-line therapy

Ovarian cancer · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Niraparib monotherapy Variant #01	—	R 102 149	28d	16.1 mo	—	18	R 1 838 677 PFS proxy	7
Olaparib and Bevacizumab Variant #01	HRD	R 73 041	21d	22.1 mo	56.5 mo	33	R 2 410 360 PFS proxy	2
Olaparib and Bevacizumab Variant #01	—	R 73 041	21d	22.1 mo	56.5 mo	33	R 2 410 360 PFS proxy	2
Olaparib monotherapy Variant #01	HRD	R 59 224	28d	13.8 mo	40.9 mo	16	R 947 584 PFS proxy	7
Olaparib monotherapy Variant #01	BRCA	R 59 224	28d	13.8 mo	40.9 mo	16	R 947 584 PFS proxy	7
Bevacizumab monotherapy Variant #08	HRD	R 57 246	21d	20.4 mo	51.6 mo	30	R 1 717 393 PFS proxy	3
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	20.4 mo	51.6 mo	30	R 1 717 393 PFS proxy	3
Pazopanib monotherapy Variant #01	—	R 22 754	28d	17.9 mo	—	20	R 455 071 PFS proxy	1
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	24.5 mo	—	27	R 59 927 PFS proxy	2
Placebo Partial	—	—	—	10.2 mo	41.1 mo	—	—	20
Rucaparib monotherapy Variant #01 Partial	—	—	28d	24.5 mo	36.0 mo	27	—	5
Observation Partial	—	—	—	20.4 mo	38.6 mo	—	—	2
Altretamine monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

13 of 13 regimens shown